/NVIV
NVIV Stock - InVivo Therapeutics Holdings Corporation
Healthcare|BiotechnologyNASDAQ
$0.32-34.28%
$0.17 (-34.28%) • Feb 12
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.94
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.35
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVIV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.32 – $0.32
TARGET (TP)$0.37
STOP LOSS$0.30
RISK/REWARD1:2.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.66
52W High$2.40
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-445,000 | $-372,000 | $-329,000 | $-322,000 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-10,650,000 | $-9,900,000 | $-9,097,000 | $-11,497,000 | $-12,767,000 |
| Net Income | $-10,179,000 | $-9,892,000 | $-9,055,000 | $-12,242,000 | $-46,244,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-6.62 | $-7.47 | $-32.80 | $-912.63 | $-3725.45 |
Company Overview
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NVIVBeat Rate
25%
Last 4 quarters
Avg Surprise
-1762.2%
EPS vs Estimate
Beats / Misses
1/3
Last 12 quarters
Latest EPS
$-0.87
Q4 2023
EPS Surprise History
Q1 22
No data
Q2 22
No data
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Feb 14, 2024 | — | — | — | — |
Q4 2023 | Nov 8, 2023 | — | $-0.87 | — | — |
Q3 2023 | Aug 9, 2023 | — | $-1.97 | — | — |
Q2 2023 | Jun 27, 2023 | — | $-1.94 | — | — |
Q1 2023 | Mar 13, 2023 | — | $-2.25 | — | — |
Q4 2022 | Nov 7, 2022 | — | $-1.98 | — | — |
Q3 2022 | Aug 8, 2022 | — | $-1.97 | — | — |
Q2 2022 | May 10, 2022 | — | $-1.94 | — | — |
Q1 2022 | Mar 7, 2022 | — | $-2.25 | — | — |
Q4 2021 | Nov 10, 2021 | — | $-1.75 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-1.75 | — | — |
Q2 2021 | May 10, 2021 | — | $-2.00 | — | — |
Q1 2021 | Mar 18, 2021 | — | $-11.24 | — | — |
Q4 2020 | Nov 6, 2020 | — | $-11.75 | — | — |
Q3 2020 | Aug 11, 2020 | — | $-12.25 | — | — |
Q2 2020 | May 13, 2020 | — | $-61.75 | — | — |
Q1 2020 | Feb 20, 2020 | $-225.00 | $-199.50 | +11.3% | ✓ BEAT |
Q4 2019 | Nov 7, 2019 | $-9.90 | $-217.72 | -2099.2% | ✗ MISS |
Q3 2019 | Aug 13, 2019 | $-9.30 | $-255.26 | -2644.7% | ✗ MISS |
Q2 2019 | May 10, 2019 | $-8.70 | $-210.21 | -2316.2% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about NVIV
What is NVIV's current stock price?
InVivo Therapeutics Holdings Corporation (NVIV) is currently trading at $0.32 per share. The stock has moved -34.28% today.
What is the analyst price target for NVIV?
No analyst price targets are currently available for this stock.
What sector is InVivo Therapeutics Holdings Corporation in?
InVivo Therapeutics Holdings Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NVIV's market cap?
InVivo Therapeutics Holdings Corporation has a market capitalization of $0.00 billion, making it a small-cap company.
Does NVIV pay dividends?
No, InVivo Therapeutics Holdings Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAXDX
Accelerate Diagnostics, Inc.
$0.03
Mkt Cap: $0.0B
BLCM
Bellicum Pharmaceuticals, Inc.
$0.07
Mkt Cap: $0.0B
CWBR
CohBar, Inc.
$0.41
Mkt Cap: $0.0B
CYTO
Altamira Therapeutics Ltd.
$0.30
Mkt Cap: $0.0B
HTGMQ
HTG Molecular Diagnostics, Inc.
$0.00
Mkt Cap: $0.0B
IMPL
Impel Pharmaceuticals Inc.
$0.04
Mkt Cap: $0.0B
INFIQ
Infinity Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
LSDI
Lucy Scientific Discovery Inc.
$0.51
Mkt Cap: $0.0B
NMTRQ
9 Meters Biopharma, Inc.
$0.00
Mkt Cap: $0.0B
TMBR
Timber Pharmaceuticals, Inc.
$0.34
Mkt Cap: $0.0B
Explore stocks similar to NVIV for comparison